Ketamine be a dissociative anesthetic dem use medically for induction den maintenance of anesthesia. Dem sanso dey use am as a treatment for depression den insyd pain management. Ketamine be an NMDA receptor antagonist wich dey account for chaw of ein psychoactive effects.
Pharmacology
Molecular targets
| Site | Value (μM) | Type | Action | Species | Ref |
|---|---|---|---|---|---|
| NMDA (N-Methyl-D-aspartate receptor) | 0.25–0.66 | Ki | Antagonist | Human | |
| MOR(μ-Opioid receptor) | 42 | Ki | Antagonist | Human | |
| MOR2 (μ-Opioid receptor) | 12.1 | Ki | Antagonist | Human | |
| KOR (κ-Opioid receptor) | 28
25 |
Ki
Ki |
Antagonist
Agonist |
Human |
|
| σ2 | 26 | Ki | ND (No data) | Rat | |
| D2 receptor (D2) | 0.5
>10 |
Ki
Ki |
Agonist
ND (No data) |
Human |
|
| Muscarinic acetylcholine receptor M1 (M1) | 45 | Ki | ND (No data) | Human | |
| α2β2 (Nicotinic acetylcholine receptor) | 92 | IC50 | Antagonist | Human | |
| α2β4 (Nicotinic acetylcholine receptor) | 29 | IC50 | Antagonist | Human | |
| Alpha-3 beta-2 nicotinic receptor (α3β2) | 50 | IC50 | Antagonist | Human | |
| Alpha-3 beta-4 nicotinic receptor (α3β4) | 9.5 | IC50 | Antagonist | Human | |
| Alpha-4 beta-2 nicotinic receptor (α4β2) | 72 | IC50 | Antagonist | Human | |
| Alpha-4 beta-4 nicotinic receptor (α4β4) | 18 | IC50 | Antagonist | Human | |
| Alpha-7 nicotinic receptor (α7) | 3.1 (Hydroxynorketamine) | IC50 | Negative allosteric modulation (NAM) | Rat | |
| ERα (Estrogen receptor alpha) | 0.34 | Ki | ND (No data) | Human | |
| NET (Norepinephrine transporter) | 82–291 | IC50 | Inhibitor | Human | |
| DAT (Dopamine transporter) | 63 | Ki | Inhibitor | Rat | |
| HCN1 (Hyperpolarization-activated cyclic nucleotide-gated channel 1) | 8–16 | EC50 | Inhibitor | Mouse | |
| TRPV1 | 1-100 | Ki | Agonist | Rat | |
| De smaller de value, de stronger de interaction plus de site. | |||||